Resources

The World Health Organization recommends two malaria vaccines—RTS,S and R21/Matrix M™—to protect children as part of a broader malaria control toolkit. These tools are saving lives where introduced in Africa; however, their vaccination schedule comprises four doses and includes new childhood vaccine visits outside of the regular childhood vaccine schedule—adding cost, delivery, and coverage challenges. Also, malaria vaccines are currently recommended for children five months of age and older, meaning that younger infants at risk of malaria remain without vaccine protection.Alternative infant schedules for malaria and other routine vaccines may prevent more disease, ease delivery challenges to achieve coverage targets, and enhance health monitoring for infants—but these potential benefits have not yet been sufficiently studied.This fact sheet describes a PATH-sponsored clinical study in Burkina Faso that is designed to identify an alternative schedule starting in early infancy that can align malaria and other routine vaccinations and maximize disease protection—potentially saving more lives in the future. The malaria vaccine used in the study is R21/Matrix M. The sites conducting the study in Burkina Faso are Groupe de Recherche Action en Santé (GRAS) in Banfora and Institut de Recherche en Science de la Santé (IRSS) in Houndé.

PATH and CEPI hosted a webinar on May 22, 2025, as a forum for researchers to present current work on biobanking for pandemic response, strengthen existing and new collaborations, and share experiences and lessons learned with the broader research community. Presentations included:An Introduction to the Coalition for Epidemic Preparedness Innovations (CEPI) Biospecimen Sourcing Initiative (Selorm Avumegah, CEPI)CEPI Perspectives on the Pandemic Agreement (Austin Liu, CEPI)Perspective on the Development of Respectful Partnerships and Aligning Stakeholder Goals With the Overall Aims of Biobanks (Daniel Simeon-Dubach, MedService)Strategies for Rapid Deployability in Biobanking: International Agency for Research on Cancer’s Experiences in Implementing Rapid Collection Initiatives (Zisis Kozlakidis, International Agency for Research on Cancers/World Health Organization)Access and Sharing Regional-Representative Characterized Specimens in a Federated and Distributed Biorepository System: The Need for Data Harmonization Across Sites and Standard Protocols (May Chu and Thomas Jaenisch, Colorado School of Public Health)

This report provides data and information on the current and projected global autodisable (AD) syringe market. It includes a PATH forecast of AD syringe demand from 2025 through 2028, which estimates a need for nearly 2 billion AD syringes in 2025 and relatively small fluctuations in global demand through 2028. Additionally, the report includes information about current market events (such as recent outbreaks), innovations (such as microarray patches), and key stakeholder interests that may impact the AD syringe market in the near future.

Improving maternal and child health is a foundational investment in long-term health and prosperity. It shapes life outcomes from birth through adulthood through safer pregnancy and deliveries, proper nutrition, and protection from deadly childhood diseases. These interventions are not only lifesaving; they are among the most cost-effective investments a government can make.As the US government seeks to redesign its approach to foreign aid, PATH’s Center for Advocacy and Policy has published a white paper identifying five key recommendations to ensure future investments can continue saving the lives moms and kids around the world while aligning with American interests and values.

Cold Chain Temperature Data Job Aid: Supporting Cold Chain Maintenance Through the Use of Temperature Data provides temperature examples with brief instructions for health care workers, technicians, and other immunization or facility staff to use temperature data to help diagnose issues with the Cold Chain Equipment (CCE) by using FridgeTag and/or Remote Temperature Monitoring Devices and more accurately respond with more proactive optimized maintenance actions.Produced by PATH, JSI, Village Reach, and New Horizons.